LIDDS AB (publ) (LIDDS.ST)
SEK 0.03
(-15.5%)
SEK 0.03
(-15.5%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 27.75 Million SEK | -27.93% |
| 2022 | 38.5 Million SEK | -5.68% |
| 2021 | 40.82 Million SEK | 24.96% |
| 2020 | 32.67 Million SEK | 37.13% |
| 2019 | 23.82 Million SEK | 128.25% |
| 2018 | 10.43 Million SEK | 35.61% |
| 2017 | 7.69 Million SEK | 16.02% |
| 2016 | 6.63 Million SEK | -15.47% |
| 2015 | 7.84 Million SEK | 11.87% |
| 2014 | 7.01 Million SEK | 75.69% |
| 2013 | 3.99 Million SEK | 4.38% |
| 2012 | 3.82 Million SEK | 4.76% |
| 2011 | 3.65 Million SEK | 90.31% |
| 2010 | 1.91 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 2.38 Million SEK | 684.87% |
| 2024 Q1 | 304 Thousand SEK | -92.12% |
| 2023 Q1 | 9.57 Million SEK | 9.23% |
| 2023 Q3 | 4.53 Million SEK | -38.62% |
| 2023 Q4 | 3.85 Million SEK | -14.9% |
| 2023 Q2 | 7.38 Million SEK | -22.88% |
| 2023 FY | 24.3 Million SEK | -36.89% |
| 2022 Q2 | 10.16 Million SEK | -1.41% |
| 2022 Q1 | 10.3 Million SEK | -8.66% |
| 2022 FY | 38.5 Million SEK | -5.68% |
| 2022 Q4 | 8.76 Million SEK | -5.46% |
| 2022 Q3 | 9.26 Million SEK | -8.81% |
| 2021 Q4 | 11.28 Million SEK | 37.1% |
| 2021 Q3 | 8.23 Million SEK | -16.92% |
| 2021 Q2 | 9.9 Million SEK | -13.02% |
| 2021 Q1 | 11.39 Million SEK | -11.35% |
| 2021 FY | 40.82 Million SEK | 24.96% |
| 2020 Q2 | 5.3 Million SEK | -33.45% |
| 2020 Q4 | 12.85 Million SEK | 95.87% |
| 2020 FY | 32.67 Million SEK | 37.13% |
| 2020 Q1 | 7.96 Million SEK | -47.42% |
| 2020 Q3 | 6.56 Million SEK | 23.79% |
| 2019 Q1 | 2.52 Million SEK | -32.41% |
| 2019 FY | 23.82 Million SEK | 128.25% |
| 2019 Q4 | 15.14 Million SEK | 444.84% |
| 2019 Q3 | 2.78 Million SEK | -17.56% |
| 2019 Q2 | 3.37 Million SEK | 33.54% |
| 2018 Q1 | 1.96 Million SEK | -36.23% |
| 2018 FY | 10.43 Million SEK | 35.61% |
| 2018 Q2 | 2.24 Million SEK | 14.26% |
| 2018 Q4 | 3.73 Million SEK | 49.78% |
| 2018 Q3 | 2.49 Million SEK | 11.14% |
| 2017 Q1 | 1.83 Million SEK | -13.34% |
| 2017 FY | 7.69 Million SEK | 16.02% |
| 2017 Q2 | 1.28 Million SEK | -30.13% |
| 2017 Q3 | 1.49 Million SEK | 16.19% |
| 2017 Q4 | 3.07 Million SEK | 106.27% |
| 2016 Q1 | 1.45 Million SEK | -10.57% |
| 2016 Q4 | 2.12 Million SEK | 32.14% |
| 2016 Q3 | 1.6 Million SEK | 10.84% |
| 2016 FY | 6.63 Million SEK | -15.47% |
| 2016 Q2 | 1.44 Million SEK | -0.55% |
| 2015 Q1 | 2.21 Million SEK | 20.99% |
| 2015 FY | 7.84 Million SEK | 11.87% |
| 2015 Q4 | 1.62 Million SEK | -10.28% |
| 2015 Q3 | 1.81 Million SEK | -17.0% |
| 2015 Q2 | 2.18 Million SEK | -1.22% |
| 2014 Q1 | 1.34 Million SEK | 20.47% |
| 2014 FY | 7.01 Million SEK | 75.69% |
| 2014 Q4 | 1.83 Million SEK | -2.98% |
| 2014 Q3 | 1.88 Million SEK | -3.58% |
| 2014 Q2 | 1.95 Million SEK | 46.04% |
| 2013 Q4 | 1.11 Million SEK | -16.05% |
| 2013 Q1 | 1.17 Million SEK | 0.0% |
| 2013 Q2 | 1.4 Million SEK | 19.42% |
| 2013 Q3 | 1.32 Million SEK | -5.89% |
| 2013 FY | 3.99 Million SEK | 4.38% |
| 2012 FY | 3.82 Million SEK | 4.76% |
| 2011 FY | 3.65 Million SEK | 90.31% |
| 2010 FY | 1.91 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 98.167% |
| AcouSort AB (publ) | 25.87 Million SEK | -7.25% |
| Active Biotech AB (publ) | 44.8 Million SEK | 38.066% |
| Alzinova AB (publ) | 36.39 Million SEK | 23.75% |
| Amniotics AB (publ) | 29.07 Million SEK | 4.54% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -89.395% |
| BioArctic AB (publ) | 89.62 Million SEK | 69.036% |
| Camurus AB (publ) | 1.05 Billion SEK | 97.381% |
| Cantargia AB (publ) | 290.01 Million SEK | 90.431% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -26.75% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 2.028% |
| Genovis AB (publ.) | 88.19 Million SEK | 68.534% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 75.883% |
| Mendus AB (publ) | 129.13 Million SEK | 78.51% |
| Kancera AB (publ) | 63.07 Million SEK | 56.003% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -402.845% |
| Lipum AB (publ) | 37.3 Million SEK | 25.612% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -282.575% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 79.581% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -69.209% |
| NextCell Pharma AB | -576.01 Thousand SEK | 4917.897% |
| OncoZenge AB (publ) | 15.9 Million SEK | -74.486% |
| Saniona AB (publ) | 1.07 Million SEK | -2476.787% |
| Simris Alg AB (publ) | 38.64 Million SEK | 28.182% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 91.368% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 92.24% |
| Xintela AB (publ) | 57.31 Million SEK | 51.581% |
| Ziccum AB (publ) | 27.87 Million SEK | 0.452% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -281.838% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 84.729% |
| CombiGene AB (publ) | 44.14 Million SEK | 37.133% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 80.591% |
| Intervacc AB (publ) | 79.78 Million SEK | 65.217% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 90.963% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 34.903% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -56.942% |
| Corline Biomedical AB | 30.16 Million SEK | 8.008% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 52.177% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 66.632% |
| Aptahem AB (publ) | 10.01 Million SEK | -177.161% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 79.396% |
| Fluicell AB (publ) | 28.61 Million SEK | 3.023% |
| Biovica International AB (publ) | 133.72 Million SEK | 79.246% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -40.232% |
| Abliva AB (publ) | 27.86 Million SEK | 0.409% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 85.658% |
| 2cureX AB (publ) | 36.51 Million SEK | 24.005% |
| I-Tech AB | 40.14 Million SEK | 30.876% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 96.771% |
| Cyxone AB (publ) | 28.21 Million SEK | 1.637% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 74.625% |
| Biosergen AB | 26.8 Million SEK | -3.517% |
| Nanologica AB (publ) | 69.88 Million SEK | 60.29% |
| SynAct Pharma AB | 224.49 Million SEK | 87.638% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 37.179% |
| BioInvent International AB (publ) | 441.4 Million SEK | 93.713% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -15.854% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 90.422% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -253.247% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 74.979% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -88.789% |